CClinicalTrials.gg
CompletedNCT04628858WARD-VASCUpdated Apr 27, 2022

Wireless Assessment of Respiratory and Circulatory Distress in Vascular Surgical Patients - An Observational Study

An observational study in Complication of Surgical Procedure, Complication of Anesthesia and Respiratory Complication, sponsored by Eske Kvanner Aasvang. Completed at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-27.

Sponsored by Eske Kvanner Aasvang · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

Vascular postsurgical patients have a high risk of morbidity and mortality. On top of that, patients undergoing vascular surgery usually have a high burden of comorbidities.

After a short stay in the post-operative ward, patients are usually transferred to a standard surgical ward.

Monitoring of physiological parameters by intermittent manual recordings 8-12 hours apart, is today's standard of care in hospitals. However, no effect on length of hospital stay, morbidity or mortality has been proven. This may be due to the up to 12 hours of unobserved time that can occur, where physiological deviations can progress resulting in clinical adverse outcomes such as myocardial infarction or stroke.

Vital sign micro events are occurrences when patient physiological parameters deviates significantly from what can be understood as normal physiology. Since adverse outcomes in patients rarely happens without deviating physiological parameters, it is to be investigated if micro events can be used to predict clinical adverse outcomes to patients. We acknowledge that during the observation period, the number of false alarms should be kept to a minimum to avoid the risk of 'alarm fatigue'

02

Conditions studied

  • Complication of Surgical Procedure
  • Complication of Anesthesia
  • Respiratory Complication
  • Circulatory; Complications
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

40 patients admitted for elective or subacute vascular surgical intervention, as noted in the inclusion criteria, will be included on the day before their surgical procedure.

Inclusion criteria

  • Patients admitted to Copenhagen University Hospital
  • Patients with Peripheral Arteriel Disease(PAD)
  • Patients undergoing open infraligamentary revascularization
  • Emergency or subacute surgery
  • Admission the day before surgery, and expected length of stay more than 2 days.

Exclusion criteria

Exclusion Criteria:

  • Patient expected not to cooperate
  • Patients with dementia or not able to give informed consent
  • Patient allergic to plaster, plastic or silicone
  • Patients with pacemaker or implantable cardioverter-defibrillator (ICD) unit
  • Patients in isolation
  • Active therapy withdrawn
  • Patients previously included in the other study branches
  • Patients with >20 mmHg in difference in systolic blood pressure between the two arms.
  • Expected discharge within less than 24 hours from possible inclusion
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (actual)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Primary group
05

What researchers measure

Primary outcomes

  1. Physiologic abnormal vital signs - Cumulative duration

    Cumulative duration of physiologic vital signs within certain thresholds outside normalcy

    Time frame: From inclusion until 4 days or discharge

Secondary outcomes

  1. Physiologic abnormal vital signs - Episodes of sustained duration

    Episodes of sustained duration of physiologic vital signs within certain thresholds outside normalcy, with different minimum durations

    Time frame: From inclusion until 4 days or discharge

Other outcomes

  1. Any serious adverse events

    In accordance with ICH-GCP: any untoward medical occurrence that(...) * Results in death * Is life-threatening * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Requires intervention to prevent permanent impairment or damage

    Time frame: 30 days

  2. Readmission

    Time frame: 6 months

  3. ICU admission

    Time frame: 6 months

  4. Mortality

    Time frame: 6 months

06

Study locations

1 site
  • Rigshospitalet
    Copenhagen, 2100, Denmark
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04628858
Lead sponsor
Eske Kvanner Aasvang
Responsible party
Eske Kvanner Aasvang (Dr. Med., Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Nov 16, 2020
Start date
Aug 17, 2020
Primary completion
Jan 23, 2021
Completion
Jul 23, 2021
Last update
Apr 27, 2022

Study contacts

Eske K Aasvang
study director · Rigshospitalet, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion